Teva Pharmaceutical Industries

The U.S. House passed the BIOSECURE Act, banning U.S. biopharma companies from working with Chinese contractors due to national security concerns. This reflects shifting global biotech dominance, with immediate supply chain challenges and long-term implications. China’s biotech leadership, built over decades, contrasts with the West’s slow prioritization. The Act may encourage the U.S. and Europe to bring resources home, but short-term consequences for manufacturing, clinical trials, and IP are significant. A comprehensive “BIOBUILD” strategy is needed to maintain biotech leadership.

Celltrion announced the full-scale launch of its CDMO business, aiming to secure new plants by year-end and invest trillions of won in a 180,000-liter production facility. The company, with its CMO know-how and global brand power, seeks to rival Lonza and offer customized services in the pharmaceutical supply cycle.

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.

Teva presented positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult schizophrenia patients at ECNP 2024. The three doses align with oral olanzapine doses, simplifying physician transitions, and no new safety signals or PDSS were observed.

Teva Pharmaceuticals announces positive results for Phase 3 SOLARIS trial evaluating TEV-‘749 in schizophrenia patients, showing significant improvements in PANSS, CGI-S, and PSP scores with no incidence of PDSS.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

DEA allows increased production of Vyvanse to address ADHD and BED treatment shortages, with 25% for domestic and 75% for foreign demand. Despite FDA approval for generic Vyvanse production, shortages persist due to active ingredient issues. DEA's quota-setting process faces criticism for causing shortages, prompting consideration of more transparent methods. Vyvanse remains the most popular stimulant among ADDitude survey respondents.

The Judicial Court of Paris revoked Sanofi’s EP 2 493 466 patent on cabazitaxel due to obviousness, marking another setback in the dispute with generic drug companies over Jevtana. French judges consistently favor generics in pharmaceutical disputes. Sanofi’s second medical use patent for cabazitaxel, used in Jevtana, faces ongoing challenges from Teva, Accord Healthcare, and Ever Pharma. The EPO Technical Boards of Appeal will hear an appeal against the patent’s grant in April 2025, and UPC cases are pending.